No clinically important response to treatment ‐ short term · patients with schizophrenia
SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG may leads to lower SENSITIVITY ‐ Global/mental state: No clinically important response… compared with ANY ANTIPSYCHOTIC DRUG (low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
CLOZAPINE probably leads to lower relapse ‐ short term compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).
4 findings from 1 review
RR 0.62 [0.45, 0.84]
19 studies · 1303 participants
Moderate
RR 0.22 [0.14, 0.34]
4 studies · 578 participants
Moderate
RR 1.04 [0.61, 1.78]
4 studies · 396 participants
Moderate
Show 1 more finding
Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia
CLOZAPINE probably leads to lower global impression: 1. Not clinically improved ‐ short term compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
3 findings from 1 review
RR 0.71 [0.64, 0.79]
4 studies · 370 participants
Moderate
RR 0.83 [0.76, 0.91]
2 studies · 648 participants
Moderate
RR 0.72 [0.66, 0.79]
14 studies · 1119 participants
Moderate
Adverse effects 1. Blood problems · patients with schizophrenia
CLOZAPINE showed no clear difference in adverse effects 1. Blood problems compared with TYPICAL ANTIPSYCHOTICS; GRADE not reported.
1 finding from 1 review
Adverse effects 4. Salivation ‐ too much · patients with schizophrenia
CLOZAPINE probably leads to higher adverse effects 4. Salivation ‐ too much compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
2 findings from 1 review
Weight gain · patients with schizophrenia
CLOZAPINE probably leads to higher adverse effects 5. Weight gain compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
2 findings from 1 review
Unable to work · patients with schizophrenia
CLOZAPINE showed no clear difference in unable to work compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).
1 finding from 1 review
Adverse effects: 1. Blood problems ‐ decreased white cell count · patients with schizophrenia
CLOZAPINE probably leads to higher adverse effects: 1. Blood problems ‐ decreased white cell count compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).
1 finding from 1 review
Death by end of trial · patients with various illnesses
Summary of findings 1. INTERCESSORY PRAYER (CONTEMPORANEOUS ) showed no clear difference in death by end of trial compared with STANDARD CARE (low certainty).
1 finding from 1 review
Clinical state: 1. Improved/not improved: intermediate or bad outcome · patients with scheduled to receive non‐emergency CABG
Summary of findings 4. AWARENESS OF INTERCESSORY PRAYER showed no clear difference in clinical state: 1. Improved/not improved: intermediate or bad outcome compared with INTERCESSORY PRAYER (moderate certainty).
1 finding from 1 review
Clinical state: 2. Significant complications (readmission to CCU) · patients with scheduled to receive non‐emergency CABG
Summary of findings 4. AWARENESS OF INTERCESSORY PRAYER showed no clear difference in clinical state: 2. Significant complications (readmission to CCU) compared with INTERCESSORY PRAYER (moderate certainty).
1 finding from 1 review
Clinical state: 1. Improved/not improved: intermediate or bad outcome · patients with various illnesses
Summary of findings 1. INTERCESSORY PRAYER (CONTEMPORANEOUS ) showed no clear difference in clinical state: 1. Improved/not improved: intermediate or bad outcome compared with STANDARD CARE (low certainty).
1 finding from 1 review
Clinical state: 2. Significant complications (readmission to CCU) · patients with various illnesses
Summary of findings 1. INTERCESSORY PRAYER (CONTEMPORANEOUS ) showed no clear difference in clinical state: 2. Significant complications (readmission to CCU) compared with STANDARD CARE (moderate certainty).
1 finding from 1 review
Leaving the study early · patients with various illnesses
Summary of findings 1. INTERCESSORY PRAYER (CONTEMPORANEOUS ) showed no clear difference in leaving the study early compared with STANDARD CARE (moderate certainty).
1 finding from 1 review
Death by end of trial · patients with blood stream infections
Summary of findings 2. INTERCESSORY PRAYER (RETROSPECTIVE) showed no clear difference in death by end of trial compared with STANDARD CARE (moderate certainty).
1 finding from 1 review
Death by end of trial · patients with scheduled to receive non‐emergency CABG
Summary of findings 3. AWARENESS OF INTERCESSORY PRAYER showed no clear difference in death by end of trial compared with STANDARD CARE (moderate certainty).
1 finding from 1 review
Clinical state: 1. Improved/not improved: intermediate or bad outcome · patients with scheduled to receive non‐emergency CABG
Summary of findings 3. AWARENESS OF INTERCESSORY PRAYER showed no clear difference in clinical state: 1. Improved/not improved: intermediate or bad outcome compared with STANDARD CARE (moderate certainty).
1 finding from 1 review
Clinical state: 2. Significant complications (readmission to CCU) · patients with scheduled to receive non‐emergency CABG
Summary of findings 3. AWARENESS OF INTERCESSORY PRAYER showed no clear difference in clinical state: 2. Significant complications (readmission to CCU) compared with STANDARD CARE (moderate certainty).
1 finding from 1 review
Death by end of trial · patients with scheduled to receive non‐emergency CABG
Summary of findings 4. AWARENESS OF INTERCESSORY PRAYER showed no clear difference in death by end of trial compared with INTERCESSORY PRAYER (moderate certainty).
1 finding from 1 review
Hospital admissions · patients with people with schizophrenia near or on discharge
DAY HOSPITAL showed no clear difference in service use: 1a. Admitted to hospital during study ‐ by 6 months compared with OUT‐PATIENT CARE (moderate certainty).
3 findings from 1 review
RR 0.58 [0.26, 1.33]
2 studies · 110 participants
Moderate
RR 0.73 [0.54, 1]
2 studies · 242 participants
Low
RR 0.71 [0.56, 0.89]
2 studies · 242 participants
Moderate